nach oben

Cancer Causes & Control

Erschienen in:

01.03.2013 | Original Paper

Baseline E₂ levels are higher in BRCA2 mutation carriers: a potential target for prevention?

verfasst von: Jayeon Kim, Kutluk Oktay

Erschienen in: Cancer Causes & Control | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

BRCA gene mutations and elevated serum estradiol (E₂) are well-known risk factors for breast cancer. The aim of this study was to investigate the association between BRCA gene mutations and serum E₂ level.

Methods

We measured baseline (menstrual cycle day 2–3) E₂ levels of 96 women with breast cancer who underwent BRCA testing.

Results

The mean age, parity, and age at menarche did not differ between women with and without BRCA1/2 mutations. Basal serum E₂ level was significantly higher in women with BRCA2 mutations compared to women with BRCA1 mutations or without BRCA mutations (71.7 ± 41.6 vs. 45.5 ± 20.7 vs. 38.5 ± 12.6 pg/ml in BRCA2 mutation carriers, BRCA1 mutation carriers, and non-carriers, respectively, p value = 0.03). Women with BRCA2 mutations had 3.1 times as great risk for high basal E₂ level (>48 pg/ml) as women without BRCA mutations after adjusting for age and BMI (95 % confidence interval: 1.3, 7.6). BRCA mutation carriers with high serum E₂ level were significantly younger than the carriers with low serum E₂ level (31.4 ± 3.1 vs. 34.7 ± 4.9 years, p = 0.04).

Conclusions

In this pilot study, we found an association between high basal serum E₂ levels and BRCA2 mutations. Our results suggest that increased production of E₂ may have a role in the pathogenesis of BRCA2-mutation-related breast cancer.

Nur mit Berechtigung zugänglich

Bray F, McCarron P, Parkin DM (2004) The changing global patterns of female breast cancer incidence and mortality. Breast Cancer Res 6(6):229–239PubMedCrossRef

Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A et al (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72(5):1117–1130PubMedCrossRef

Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J et al (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The breast cancer linkage consortium. Am J Hum Genet 62(3):676–689PubMedCrossRef

Zhong Q, Chen CF, Li S, Chen Y, Wang CC, Xiao J, Chen PL, Sharp ZD, Lee WH (1999) Association of BRCA1 with the hRad50-hMre11-p95 complex and the DNA damage response. Science 285(5428):747–750PubMedCrossRef

Oktay K, Kim JY, Barad D, Babayev SN (2010) Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks. J Clin Oncol 28(2):240–244PubMedCrossRef

Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, Ellis NA, Boyd J, Borgen PI, Barakat RR et al (2002) Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346(21):1609–1615PubMedCrossRef

Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van’t Veer L, Garber JE, Evans G, Isaacs C, Daly MB, Matloff E et al (2002) Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346(21):1616–1622PubMedCrossRef

Rebbeck TR, Levin AM, Eisen A, Snyder C, Watson P, Cannon-Albright L, Isaacs C, Olopade O, Garber JE, Godwin AK et al (1999) Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 91(17):1475–1479PubMedCrossRef

Fisher B (1999) Highlights from recent National Surgical Adjuvant Breast and bowel project studies in the treatment and prevention of breast cancer. CA Cancer J Clin 49(3):159–177PubMedCrossRef

10.

King MC, Wieand S, Hale K, Lee M, Walsh T, Owens K, Tait J, Ford L, Dunn BK, Costantino J et al (2001) Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 286(18):2251–2256PubMedCrossRef

11.

Seery LT, Knowlden JM, Gee JM, Robertson JF, Kenny FS, Ellis IO, Nicholson RI (1999) BRCA1 expression levels predict distant metastasis of sporadic breast cancers. Int J Cancer 84(3):258–262PubMedCrossRef

12.

Hu Y, Ghosh S, Amleh A, Yue W, Lu Y, Katz A, Li R (2005) Modulation of aromatase expression by BRCA1: a possible link to tissue-specific tumor suppression. Oncogene 24(56):8343–8348PubMedCrossRef

13.

Malone JL, Nelson AC, Lieberman R, Anderson S, Holt JT (2009) Oestrogen-mediated phosphorylation and stabilization of BRCA2 protein in breast. J Pathol 217(3):380–388PubMedCrossRef

14.

Lee S, Ozkavukcu S, Heytens E, Moy F, Alappat RM, Oktay K (2011) Anti-Mullerian hormone and antral follicle count as predictors for embryo/oocyte cryopreservation cycle outcomes in breast cancer patients stimulated with letrozole and follicle stimulating hormone. J Assist Reprod Genet 28(7):651–656PubMedCrossRef

15.

Stovall DW, Toma SK, Hammond MG, Talbert LM (1991) The effect of age on female fecundity. Obstet Gynecol 77(1):33–36PubMed

16.

Eliassen AH, Missmer SA, Tworoger SS, Spiegelman D, Barbieri RL, Dowsett M, Hankinson SE (2006) Endogenous steroid hormone concentrations and risk of breast cancer among premonopausal women. J Nat Cancer Inst 98(19):1406–1415PubMedCrossRef

17.

Yen HY, Gabet Y, Liu Y, Martin A, Wu NL, Pike MC, Frenkel B, Maxson R, Dubeau L (2012) Alterations in Brca1 expression in mouse ovarian granulosa cells have short-term and long-term consequences on estrogen-responsive organs. Lab Invest 92(6):802–811PubMedCrossRef

18.

Bramley M, Clarke RB, Howell A, Evans DG, Armer T, Baildam AD, Anderson E (2006) Effects of oestrogens and anti-oestrogens on normal breast tissue from women bearing BRCA1 and BRCA2 mutations. Br J Cancer 94(7):1021–1028PubMedCrossRef

19.

Hong H, Yen HY, Brockmeyer A, Liu Y, Chodankar R, Pike MC, Stanczyk FZ, Maxson R, Dubeau L (2010) Changes in the mouse estrus cycle in response to BRCA1 inactivation suggest a potential link between risk factors for familial and sporadic ovarian cancer. Cancer Res 70(1):221–228PubMedCrossRef

20.

Metcalfe K, Lynch HT, Ghadirian P, Tung N, Olivotto I, Warner E, Olopade OI, Eisen A, Weber B, McLennan J et al (2004) Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 22(12):2328–2335PubMedCrossRef

21.

Williamson LM, Lees-Miller SP (2011) Estrogen receptor alpha-mediated transcription induces cell cycle-dependent DNA double-strand breaks. Carcinogenesis 32(3):279–285PubMedCrossRef

22.

Patel KJ, Yu VP, Lee H, Corcoran A, Thistlethwaite FC, Evans MJ, Colledge WH, Friedman LS, Ponder BA, Venkitaraman AR (1998) Involvement of Brca2 in DNA repair. Mol Cell 1(3):347–357PubMedCrossRef

23.

Frankish H (2001) BRCA1 has a pivotal role in repairing DNA. Lancet 357(9269):1678

24.

Lonning PE, Helle H, Duong NK, Ekse D, Aas T, Geisler J (2009) Tissue estradiol is selectively elevated in receptor positive breast cancers while tumour estrone is reduced independent of receptor status. J Steroid Biochem Mol Biol 117(1–3):31–41PubMedCrossRef

25.

Farhat GN, Cummings SR, Chlebowski RT, Parimi N, Cauley JA, Rohan TE, Huang AJ, Vitolins M, Hubbell FA, Manson JE et al (2011) Sex hormone levels and risks of estrogen receptor-negative and estrogen receptor-positive breast cancers. J Natl Cancer Inst 103(7):562–570PubMedCrossRef

Titel: Baseline E2 levels are higher in BRCA2 mutation carriers: a potential target for prevention?
verfasst von: Jayeon Kim
Kutluk Oktay
Publikationsdatum: 01.03.2013
Verlag: Springer Netherlands
Erschienen in: Cancer Causes & Control / Ausgabe 3/2013
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-012-0127-3

Springer Medizin

Baseline E₂ levels are higher in BRCA2 mutation carriers: a potential target for prevention?

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2013

Selected cancers with increasing mortality rates by educational attainment in 26 states in the United States, 1993–2007

Case–control study of lifetime alcohol intake and prostate cancer risk

Polymorphisms in genes related to one-carbon metabolism are not related to pancreatic cancer in PanScan and PanC4

Association between habitual dietary flavonoid and lignan intake and colorectal cancer in a Spanish case–control study (the Bellvitge Colorectal Cancer Study)

Self-reported side effects of breast cancer treatment: a cross-sectional study of incidence, associations, and the influence of exercise

Diabetes and risk of bladder cancer among postmenopausal women in the Iowa women’s health study

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie